RxDoctor Payments Data

Leanne Veary

Physician Assistant · Hyannis, MANPI 1275089377

Payments from drug & device makers

$5,803in general payments, 2019–2025

Across 216 payments — averaging $26.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$836
  • Takeda Pharmaceuticals U.S.A., Inc.$376
  • Phathom Pharmaceuticals, Inc.$303
  • Ferring Pharmaceuticals Inc.$285
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,76499%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,803 in reported general payments places this provider in the 95th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts

Medicare billing

Part B allowed, 2024
$28,185
Medicare patients
209
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab37$250,199
XifaxanRifaximin24$64,007
CreonLipase/Protease/Amylase15$62,597
LinzessLinaclotide52$56,092
Mesalamine25$9,872
VoqueznaVonoprazan Fumarate11$8,798
ClenpiqSod Picosulf/Mag Ox/Citric Ac39$6,915
SutabSod Sulf/Pot Chloride/Mag Sulf36$5,783
Budesonide EcBudesonide16$5,573
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl261$4,097
Pantoprazole Sodium133$2,712
Colestipol Hcl31$2,544
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates31$1,956
CholestyramineCholestyramine (With Sugar)14$1,618
Omeprazole53$1,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,281$118,68967 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$836$64,00724 claims
Phathom Pharmaceuticals, Inc.Voquezna$303$8,79811 claims
Ferring Pharmaceuticals Inc.Clenpiq$285$6,91539 claims
Braintree Laboratories, Inc.Sutab$151$5,78336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →